Theravance Biopharma touts expanded FDA nod for GSK’s Trelegy Ellipta inhaler

Theravance Biopharma‘s (NSDQ:TBPH) said today that the FDA granted expanded indications for GlaxoSmithKline‘s (NYSE:GSK) Trelegy Ellipta inhaler, now approved for use to treat a broader population of chronic obstructive pulmonary disease patients.

With the expansion, the inhaler is now cleared for COPD patients with airflow limitations and for those who have experienced an acute worsening of respiratory symptoms, the Dublin-based company said. The system is intended as a long-term, once-daily maintenance to treat airflow obstructions, as well as to reduce exacerbations of COPD.

Read the whole story on our sister site, Drug Delivery Business

The post Theravance Biopharma touts expanded FDA nod for GSK’s Trelegy Ellipta inhaler appeared first on MassDevice.

from MassDevice https://ift.tt/2Jn3acj